BRICS Diabetes Drugs Market, by Injectables (Insulin, Exenatide), Oral Antidiabetic Drugs (Metformin, Sulfonylureas, Thaizolidinediones, Dipeptidyl Inhibitors, Meglitinides, Alpha Glucosidase Inhibitors, Combination Medications), Geography (Brazil, Russia, India, China, South Africa) Forecast to 2026

Market Scenario

BRICS Diabetes Drugs Market is expected to reach USD 61.59 billion by 2026, from 12.7 billion in 2016 at a CAGR of 17.5%.(Detailed analysis of the market CAGR is provided in the report) BRICS Diabetes Drugs Market Diabetes is a chronic disease characterized by high blood sugar level, the main cause of diabetes is improper functioning of the pancreas which secretes insulin. Diabetes Drug market is completely based on drug used to lower glucose level in the blood, with the help of oral hypoglycemic agents or oral antihyperglycemic agents to ensure treatment of diabetes Selection of different types of diabetes drug completely depends upon • Nature of the Diabetes • Age • Situation of the Person Various driving factors for diabetes drug market are increased life expectancy, changing lifestyles, and the rising incidence of obesity. While using diabetes drugs and drug infusion devices safety and security precautions taken by patient could cause challenges for growth of the market. Diabetes in Russia is also expected to reach at 21.5 million patients by 2026.India and China has the highest number of diabetes patients in the world due to increased aging population in these regions. China alone is expected to have more than 73 million diabetes patients by 2026. The rising incidence of diabetes in BRICS is estimated to reach astonishingly at 135 million patients by 2026, or about 37% of the world’s diabetic population. Among BRICS nations Brazil is expected to show lower growth rate due to patent expiry of various diabetes drugs. Eli Lilly and Novo Nordisk are the two smarter organizations in this market that has offered easy-to-use insulin versions to grab the market share in the Indian market for diabetes drugs. Key Highlights: • Opportunity analysis in the BRICS Diabetes Drugs market for the stakeholders and competitive landscape for the market leaders and followers • Competitive developments, key trends, R&D expenditure, expansions, mergers & acquisitions, supply chain analysis, new product launches, In BRICS Diabetes Drugs market • BRICS Diabetes Drugs market divided on the basis of Oral Antidiabetic Drugs, Injectables and Country. • BRICS Diabetes Drugs market analysis and forecast for five major regions Brazil,Russia, India, China, and South Africa. • Market forecasting in terms of value in size of the BRICS Diabetes Drugs market and region wise volumes including Brazil, Russia, India, China, and South Africa. • Strategic micro markets analysis (refer to further segments and sub-segments) with respect to individual growth trends, winning edge imperatives, future prospects, and contribution to the total BRICS Diabetes Drugs market • Company Profiling in strategic perspective of key players in the industry in BRICS Diabetes Drugs market and comprehensively analysis of their core competencies Years that have been considered for the study are as follows: • Base Year – 2016 • Estimated Year – 2017 • Forecast Period – 2016 to 2026 For company profiles, 2016 has been considered as the base year. In cases, wherein information was unavailable for the base year, the years prior to it have been considered Research Methodology: Objective of study is to estimate the size of the BRICS Diabetes Drugs market for 2017 and projects its demand till 2026 with quantitative and qualitative analysis of BRICS Diabetes Drugs market. Industry experts have studied various industry journals, directories, have referred information available with various associations to identify, collect information and to put it in articulated format to make useful for all stake holders in the industry. Primary research has been done and various industry experts and suppliers from worlds wide have given their inputs to make the study more accurate BRICS Diabetes Drugs Market Key players in the value chain for BRICS Diabetes Drugs market from raw material supplier side and service providers are included in reports. Some of them are: • Takeda Pharmaceuticals Company • Shreya Life Sciences Pvt Ltd • Bayer Healthcare Ag • Zydus Cadila Healthcare Ltd • Dr. Reddy's Laboratories Ltd • Boehringer Ingelheim • Glenmark Pharmaceuticals Ltd. • Bristol-Myers Squibb • Sanofi-Aventis • Merck & Co. Inc. • Roche Holding Ltd • Eli Lilly And Company • Aurobindo Pharma Ltd • Novo Nordisk A/S • GlaxoSmithKline Plc Key Target Audience for this Report: • Research and Consulting Companies • Healthcare Institutions (Individual Surgeons, Medical Schools, Group Practices, Hospitals, and Governing Bodies) • Diabetes Drugs Market Research Associations • Diabetes drug Manufacturers & Distributors Scope of the report: Research report categorizes the BRICS Diabetes Drugs market based on Oral antidiabetic drugs, Injectables and Country. Market size by value is estimated and forecasted with the revenues of leading companies operating in the BRICS Diabetes Drugs market with key developments in companies and market trends Global Brics Diabetes Drugs Market By Injectables • Insulin • Exenatide Global Brics Diabetes Drugs Market By Oral Antidiabetic Drugs • Metformin • Sulfonylureas • Thaizolidinediones • Dipeptidyl Inhibitors • Meglitinides • Alpha Glucosidase Inhibitors • Combination Medications Global Brics Diabetes Drugs Market, By Country • Brazil • Russia • India • China • South Africa Available Customizations: With the given market data, Maximize Market Research offers customization of report and scope of the report as per the requirement   Hearing Aids Market -Industry Analysis and Forecast (2017 - 2026)

Table of Contents

1.EXECUTIVE SUMMARY 2.RESEARCH METHODOLOGY 2.1. Market Definition 2.2. Market Scope 2.3. Data Sources 3.MARKET DYNAMICS 3.1. Market Drivers 3.2. Market Restraints 3.3. Market Opportunities 4.END-USER OVERVIEW 4.1. Value Chain Analysis 4.2. Key Trends 5. BRICS DIABETES DRUGS MARKET BY INJECTABLES (2016-2026) 5.1. Introduction 5.2. Global BRICS Diabetes Drugs Market By Insulin 5.2.1. Insulin Market Overview 5.2.2. Insulin Market Size & Forecast 5.3. Global BRICS Diabetes Drugs Market By Exenatide 5.3.1. Exenatide Market Overview 5.3.2. Exenatide Market Size & Forecast 6. BRICS DIABETES DRUGS MARKET BY ORAL ANTIDIABETIC DRUGS (2016-2026) 6.1. Introduction 6.2. Global BRICS Diabetes Drugs Market By Metformin 6.2.1. Metformin Market Overview 6.2.2. Metformin Market Size & Forecast 6.3. Global BRICS Diabetes Drugs Market By Sulfonylureas 6.3.1. Sulfonylureas Market Overview 6.3.2. Sulfonylureas Market Size & Forecast 6.4. Global BRICS Diabetes Drugs Market By Thaizolidinediones 6.4.1. Thaizolidinediones Market Overview 6.4.2. Thaizolidinediones Market Size & Forecast 6.5. Global BRICS Diabetes Drugs Market By Dipeptidyl Inhibitors 6.5.1. Dipeptidyl Inhibitors Market Overview 6.5.2. Dipeptidyl Inhibitors Market Size & Forecast 6.6. Global BRICS Diabetes Drugs Market By Meglitinides 6.6.1. Meglitinides Market Overview 6.6.2. Meglitinides Market Size & Forecast 6.7. Global BRICS Diabetes Drugs Market By Alpha Glucosidase Inhibitors 6.7.1. Alpha Glucosidase Inhibitors Market Overview 6.7.2. Alpha Glucosidase Inhibitors Market Size & Forecast 6.8. Global BRICS Diabetes Drugs Market By Combination Medications 6.8.1. Combination Medications Market Overview 6.8.2. Combination Medications Market Size & Forecast 7. BRICS DIABETES DRUGS MARKET, BY COUNTRY(2016-2026) 7.1. Brazil Diabetes Drugs Market 7.1.1. Brazil Diabetes Drugs Market by Injectables 7.1.2. Brazil Diabetes Drugs Market by Oral antidiabetic drugs 7.1.3. Brazil Diabetes Drugs Market by Regions 7.2. Russia Diabetes Drugs Market 7.2.1. Russia Diabetes Drugs Market by Injectables 7.2.2. Russia Diabetes Drugs Market by Oral antidiabetic drugs 7.2.3. Russia Diabetes Drugs Market by Regions 7.3. India Diabetes Drugs Market 7.3.1. India Diabetes Drugs Market by Injectables 7.3.2. India Diabetes Drugs Market by Oral antidiabetic drugs 7.3.3. India Diabetes Drugs Market by Regions 7.4. China Diabetes Drugs Market 7.4.1. China Diabetes Drugs Market by Injectables 7.4.2. China Diabetes Drugs Market by Oral antidiabetic drugs 7.4.3. China Diabetes Drugs Market by Regions 7.5. South Africa Diabetes Drugs Market 7.5.1. South Africa Diabetes Drugs Market by Injectables 7.5.2. South Africa Diabetes Drugs Market by Oral antidiabetic drugs 7.5.3. South Africa Diabetes Drugs Market by Regions 8.MARKET COMPETITION ANALYSIS 8.1. Market Share/Positioning Analysis 8.2. Key Innovators 8.3. Company Profiles 8.3.1. Takeda Pharmaceuticals Company 8.3.1.1. Overview 8.3.1.2. Delivery Mode /Service End-User 8.3.1.3. Strategy 8.3.1.4. Key Developments 8.3.2. Shreya Life Sciences Pvt Ltd 8.3.2.1. Overview 8.3.2.2. Delivery Mode /Service End-User 8.3.2.3. Strategy 8.3.2.4. Key Developments 8.3.3. Bayer Healthcare Ag 8.3.3.1. Overview 8.3.3.2. Delivery Mode /Service End-User 8.3.3.3. Strategy 8.3.3.4. Key Development 8.3.4. Zydus Cadila Healthcare Ltd 8.3.4.1. Overview 8.3.4.2. Delivery Mode /Service End-User 8.3.4.3. Strategy 8.3.4.4. Key Developments 8.3.5. Dr. Reddy's Laboratories Ltd 8.3.5.1. Overview 8.3.5.2. Delivery Mode /Service End-User 8.3.5.3. Strategy 8.3.5.4. Key Developments 8.3.6. Boehringer Ingelheim 8.3.6.1. Overview 8.3.6.2. Delivery Mode /Service End-User 8.3.6.3. Strategy 8.3.6.4. Key Developments 8.3.7. Glenmark Pharmaceuticals Ltd 8.3.7.1. Overview 8.3.7.2. Delivery Mode /Service End-User 8.3.7.3. Strategy 8.3.7.4. Key Developments 8.3.8. Bristol-Myers Squibb 8.3.8.1. Overview 8.3.8.2. Delivery Mode /Service End-User 8.3.8.3. Strategy 8.3.8.4. Key Developments 8.3.9. Sanofi-Aventis 8.3.9.1. Overview 8.3.9.2. Delivery Mode /Service End-User 8.3.9.3. Strategy 8.3.9.4. Key Developments 8.3.10. Merck & Co. Inc. 8.3.10.1. Overview 8.3.10.2. Delivery Mode /Service End-User 8.3.10.3. Strategy 8.3.10.4. Key Developments 8.3.11. Roche Holding Ltd 8.3.11.1. Overview 8.3.11.2. Delivery Mode /Service End-User 8.3.11.3. Strategy 8.3.11.4. Key Developments 8.3.12. Eli Lilly And Company 8.3.12.1. Overview 8.3.12.2. Delivery Mode /Service End-User 8.3.12.3. Strategy 8.3.12.4. Key Developments 8.3.13. Aurobindo Pharma Ltd 8.3.13.1. Overview 8.3.13.2. Delivery Mode /Service End-User 8.3.13.3. Strategy 8.3.13.4. Key Developments 8.3.14. Novo Nordisk A/S 8.3.14.1. Overview 8.3.14.2. Delivery Mode /Service End-User 8.3.14.3. Strategy 8.3.14.4. Key Developments 8.3.15. GlaxoSmithKline Plc 8.3.15.1. Overview 8.3.15.2. Delivery Mode /Service End-User 8.3.15.3. Strategy 8.3.15.4. Key Developments LIST OF TABLES Table no.1 Brazilian diabetes drugs market, by products 2016 – 2026 ($Millions) Table no.2 Russian diabetes drugs market, by products 2016 – 2026 ($Millions) Table no.3 Indian diabetes drugs market, by products 2016 – 2026 ($Millions) Table no.4 Chinese diabetes drugs market, by products 2016 – 2026 ($Millions) Table no.5 South Africa diabetes drugs market, by products 2016 – 2026 ($Millions) Table no.6 BRICS injectables market, by products 2016 – 2026 ($Millions) Table no.7 BRICS injectables market, by Country 2016 – 2026 ($Millions) Table no.8 BRICS insulin market, by country 2016 – 2026 ($Millions) Table no.9 BRICS incretin mimetics market by country 2016 – 2026 ($Millions) Table no.10 BRICS oral antidiabetic drugs market, by products 2016 – 2026 ($Millions) Table no.11 BRICS oral antidiabetic drugs market, by country 2016 – 2026 ($Millions) Table no.12 BRICS metformin market, by Country 2016 – 2026 ($Millions) Table no.13 BRICS sulfonylurea market, by country 2016 – 2026 ($Millions) Table no.14 BRICS thiazolidinediones market, by country 2016 – 2026 ($Millions) Table no.15 BRICS meglitinides market, by geography 2016 – 2026 ($Millions) Table no.16 BRICS alpha glucosidase inhibitors market, by Country 2016 – 2026 ($Millions) Table no.17 BRICS dipeptidyl peptidase inhibitors market, by country 2016 – 2026 ($Millions) Table no.18 BRICS combination medications market, by country 2016 – 2026 ($Millions) Table no.19 Competitive developments in BRICS (2010-January 2016) LIST OF FIGURES Figure no. 1 Prevalence of diabetes in BRICS (2016) Figure no. 2 Rising diabetic population in BRICS (2016 – 2026 ) Figure no. 3 India & China attract market players Figure no. 4 Comparative analysis of the market aspects of BRICS Figure no. 5 Market share of diabetes drugs (2016) Figure no. 6 Shift of market from oral anti-diabetic drugs to insulin from 2012 to 2016 Figure no. 7 Dipeptidyl peptidase inhibitors - emerging class of drugs (2016) Figure no. 8 Gap analysis of anti-diabetic drugs Figure no. 9 Estimated prevalence of diabetes in age groups Figure no. 10 Levels of diabetes therapy Figure no. 11 Market share of anti-diabetic drugs in BRICS WRT prescription (%) Figure no. 12 Evolution of sulfonylurea Figure no. 13 Approximate share of ant diabetic drugs WRT revenues (%) Figure no. 14 Company strategic focus Figure no. 15 Profitable collaboration with glucose monitoring equipment manufacturers Figure no. 16 Key market players in competitive development Figure no. 17 Oral ant diabetic drugs market share analysis Figure no. 18 Insulin market share analysis Figure no. 19 Evolution of antidiabetes drugs

Inquiry Before Buying

Request Sample

About This Report

Report ID 356
Category Healthcare
Publisher Name
No of Pages
Total Views
Published Date
Contact Us
Call Now